Skip to main content
رجوع
Watch Compare

BioXcel Therapeutics, Inc.

جودة البيانات: 100%
BTAI
NASDAQ Manufacturing Chemicals
KWD 1.05
▼ KWD 0.01 (-0.94%)
6 months return
—
Momentum
Neutral
Net margin
-10887.38%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-71.67%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net Margin-10887.38%
Op. Margin-7859.97%

الأمان

Debt / Equity
N/A
Current Ratio1.17
Interest Coverage-3.29

التقييم

PE (TTM|NTM)
-0.42 | -0.64
أعلى من متوسط القطاع (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -57.62 M
Capital efficient — spends only 0.00% of revenue on capex

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

4 محللين
Hold
+1233.3%
upside to target
الحالي
KWD 1.05
Consensus Target
KWD 14.00
KWD 1.00
أدنى
KWD 38.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-0.64
ربحية السهم المستقبلية
-KWD 1.65
الإيرادات المقدّرة
18.93 M

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 0.49 · Rev Est: 408,650.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 1.50 -KWD 2.45 -KWD 2.16 — — —
Estimate -KWD 3.04 -KWD 1.56 -KWD 1.34 -KWD 0.64 -KWD 0.49 -KWD 0.37
المفاجأة +50.66% -56.72% -61.48% — — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -71.67% Revenue Growth (3Y) -31.79%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -10887.38%
Revenue (TTM) 642,000.0 Net Income (TTM) -69.90 M
ROE N/A ROA -198.06%
Gross Margin N/A Operating Margin -7859.97%
Net Margin -10887.38% Free Cash Flow (TTM) -57.62 M
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 1.17
Debt / Equity N/A Current Ratio 1.17
Interest Coverage -3.29 Asset Turnover 0.02
Working Capital 6.60 M Tangible Book Value -88.92 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0.42 · EV/EBITDA: N/A
P/E Ratio -0.42 Forward P/E -0.64
P/B Ratio N/A P/S Ratio 45.55
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 1.54 Fwd Earnings Yield N/A
FCF Yield -197.04%
Market Cap 29.24 M Enterprise Value 102.19 M

Per Share

EPS: -5.73 · FCF/Share: -2.13
EPS (Diluted TTM) -5.73 Revenue / Share 0.02
FCF / Share -2.13 OCF / Share -2.13
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 82.43% · CapEx/Rev: 0.00%
CapEx / Revenue 0.00% FCF Conversion 82.43%
SBC-Adj. FCF -61.80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 642,000.0 2.27 M 1.38 M 375,000.0 —
Net Income -69.90 M -59.60 M -179.05 M -165.76 M -106.93 M
EPS (Diluted) -5.73 -23.51 -6.15 -5.92 -4.05
Gross Profit — — — — —
Operating Income -50.46 M -67.25 M -171.78 M -159.65 M -106.94 M
EBITDA — — — — —
R&D Expenses 30.25 M 30.44 M 84.33 M 91.24 M 52.71 M
SG&A Expenses 20.49 M 34.49 M 83.41 M 68.76 M —
D&A — — — — 297,000.0
Interest Expense 15.33 M 14.66 M 13.31 M 8.21 M 40,000.0
Income Tax 0.0 0.0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 44.92 M 38.34 M 73.70 M 205.85 M 239.44 M
Total Liabilities 140.38 M 131.44 M 130.21 M 129.08 M 17.77 M
Shareholders' Equity -95.46 M -93.10 M -56.51 M 76.78 M 221.67 M
Total Debt 109.59 M 102.51 M 100.60 M 93.05 M —
Cash & Equivalents 28.42 M 29.85 M 65.22 M 193.73 M 232.97 M
Current Assets 44.69 M 37.39 M 72.14 M 202.87 M 236.81 M
Current Liabilities 53.93 M 22.23 M 27.27 M 32.90 M 16.67 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -0.4 -1.5
P/B — 1.6
ROE % — -54.5
Net Margin % -10887.4 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3